Milnacipran hydrochloride solution, 1.0mg/mL in methanol (as free base), ampule of 1mL, certified reference material, Cerilliant

SKU:
M-145-1ML
  • $213.00

    • Description

    Milnacipran hydrochloride solution 

    1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant

    Empirical Formula (Hill Notation):
    C15H23ClN2O
    CAS Number:
    101152-94-7
    Molecular Weight:
    282.81
    EC Number:
    200-659-6
    MDL number:
    MFCD27978092
    UNSPSC Code:
    41116107
    PubChem Substance ID:
    329817879
    NACRES:
    NA.24

    Properties

    grade

    certified reference material

    Quality Level

    300

    form

    liquid

    feature

    Snap-N-Spike®/Snap-N-Shoot®

    packaging

    ampule of 1 mL

    manufacturer/tradename

    Cerilliant®

    concentration

    1.0 mg/mL in methanol (as free base)

    technique(s)

    gas chromatography (GC): suitable
    liquid chromatography (LC): suitable

    application(s)

    clinical testing

    format

    single component solution

    storage temp.

    −20°C

    SMILES string

    CCN(CC)C([C@]1(C2=CC=CC=C2)C[C@@H]1CN)=O.Cl

    InChI

    1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m1./s1

    InChI key

    XNCDYJFPRPDERF-PBCQUBLHSA-N

    Description

    General description

    Milnacipran, sold under the brand names Savella®, Ixel®, Dalcipran®, or Toledomin, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used in the treatment of depression. In 2009, the US Food and Drug Administration (FDA) approved milnacipran for management of the chronic pain disorder fibromyalgia, making it only the third drug approved in the US for this indication besides duloxetine and pregabalin.

    Application


      • Anesthetic and Analgesic Applications of Milnacipran: Review on new serotonin-norepinephrine reuptake inhibitors, highlighting Milnacipran hydrochloride′s role in anesthetic and analgesic applications, discussing its impact on pain management strategies (Fanelli et al., 2021).

      • Sustained Release Delivery System for Milnacipran: Development of a novel chitosan-polycaprolactone based mucoadhesive gastro-retentive drug delivery system for Milnacipran HCl, aimed at improving bioavailability and enhancing patient compliance (Hussain et al., 2020).

      • Comparative Review of Levomilnacipran and Milnacipran: Analysis of Levomilnacipran′s effectiveness compared to Milnacipran in treating major depressive disorder, focusing on efficacy, tolerability, and patient outcomes (Gautam et al., 2019).

      • Antidepressant Efficacy and Side Effects: Network meta-analysis of 21 antidepressants, including Milnacipran, assessing their side effect profiles and comparative tolerability in the acute treatment of major depression (Tomlinson et al., 2019).

    Legal Information

    CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
    Dalcipran is a registered trademark of Pierre Fabre Medicament
    Ixel is a registered trademark of Pierre Fabre Medicament
    Savella is a registered trademark of Forest Laboratories, Inc.
    Snap-N-Shoot is a registered trademark of Cerilliant Corporation
    Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

    Safety Information

    signalword

    Danger

    hcodes

    H225,H301 + H311 + H331,H370

    pcodes

    P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311

    Hazard Classifications

    Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

    target_organs

    Eyes

    wgk_germany

    WGK 1